Opinion

Published in:
Volume 7 / Year 2018 / Issue 2

Rationalizing FDA guidance on biosimilars—expediting approvals and acceptance

Author(s):

Abstract: Biosimilar drugs have suffered slow entrance and acceptance rates in the US market, due not only to common misperceptions among the public but also US Food and Drug Administration… Read More »

Go Back Print